A quality improvement study : Optimizing pneumococcal vaccination rates in children with cochlear implants
Copyright © 2022 Elsevier Ltd. All rights reserved..
Children with cochlear implants are at increased risk of invasive pneumococcal disease, with national and international guidelines recommending additional pneumococcal vaccines for these children. This study aimed to examine the pneumococcal immunization status and rate of invasive pneumococcal disease in children with cochlear implants at a tertiary paediatric hospital over a 12-year period. Additionally, the impacts of vaccination reminders and a dedicated immunization clinic on pneumococcal vaccination rates were assessed. This quality improvement study included 200 children who had received a cochlear implant through the Children's Hearing Implant Program at a tertiary paediatric hospital servicing the state of Western Australia. The majority of children (88%) were not up to date with additionally recommended pneumococcal vaccinations. Over the 12-year study period, 2% of children developed invasive pneumococcal disease associated with cochlear implant infections. Generic and personalized electronic immunization reminders improved pneumococcal vaccine up-take in this paediatric cochlear implant setting from 12% (19/153) at baseline to 49% (75/153, p < 0.0001) post implementation. The value of a nurse-led dedicated immunization clinic was also demonstrated with all children (42/42, 100%) up to date with Prevenar13 and the majority (34/42, 81%) up to date with Pneumovax23 post initiation of this referral pathway. These data support the expansion of this model to other medically-at-risk paediatric groups that have been highlighted consistently to be under-vaccinated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Vaccine - 40(2022), 32 vom: 30. Juli, Seite 4531-4537 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tay, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cochlear implants |
|---|
| Anmerkungen: |
Date Completed 21.07.2022 Date Revised 08.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2022.06.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342398520 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342398520 | ||
| 003 | DE-627 | ||
| 005 | 20231226014025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2022.06.022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342398520 | ||
| 035 | |a (NLM)35718588 | ||
| 035 | |a (PII)S0264-410X(22)00769-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tay, S |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A quality improvement study |b Optimizing pneumococcal vaccination rates in children with cochlear implants |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2022 | ||
| 500 | |a Date Revised 08.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Children with cochlear implants are at increased risk of invasive pneumococcal disease, with national and international guidelines recommending additional pneumococcal vaccines for these children. This study aimed to examine the pneumococcal immunization status and rate of invasive pneumococcal disease in children with cochlear implants at a tertiary paediatric hospital over a 12-year period. Additionally, the impacts of vaccination reminders and a dedicated immunization clinic on pneumococcal vaccination rates were assessed. This quality improvement study included 200 children who had received a cochlear implant through the Children's Hearing Implant Program at a tertiary paediatric hospital servicing the state of Western Australia. The majority of children (88%) were not up to date with additionally recommended pneumococcal vaccinations. Over the 12-year study period, 2% of children developed invasive pneumococcal disease associated with cochlear implant infections. Generic and personalized electronic immunization reminders improved pneumococcal vaccine up-take in this paediatric cochlear implant setting from 12% (19/153) at baseline to 49% (75/153, p < 0.0001) post implementation. The value of a nurse-led dedicated immunization clinic was also demonstrated with all children (42/42, 100%) up to date with Prevenar13 and the majority (34/42, 81%) up to date with Pneumovax23 post initiation of this referral pathway. These data support the expansion of this model to other medically-at-risk paediatric groups that have been highlighted consistently to be under-vaccinated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cochlear implants | |
| 650 | 4 | |a Immunization clinics | |
| 650 | 4 | |a Immunization reminders | |
| 650 | 4 | |a Pediatric | |
| 650 | 4 | |a Pneumococcal vaccine | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 700 | 1 | |a Bowen, A C |e verfasserin |4 aut | |
| 700 | 1 | |a Blyth, C C |e verfasserin |4 aut | |
| 700 | 1 | |a Clifford, P |e verfasserin |4 aut | |
| 700 | 1 | |a Clack, R |e verfasserin |4 aut | |
| 700 | 1 | |a Ford, T |e verfasserin |4 aut | |
| 700 | 1 | |a Herbert, H |e verfasserin |4 aut | |
| 700 | 1 | |a Kuthubutheen, J |e verfasserin |4 aut | |
| 700 | 1 | |a Mascaro, F |e verfasserin |4 aut | |
| 700 | 1 | |a O'Mahoney, A |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, S |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, T |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, A J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 40(2022), 32 vom: 30. Juli, Seite 4531-4537 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:32 |g day:30 |g month:07 |g pages:4531-4537 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2022.06.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 32 |b 30 |c 07 |h 4531-4537 | ||